Use this link for 5% off at iHerb.
To address the growing use of ad blockers we now use affiliate links to sites like Amazon.com, streaming services, and others. Affiliate links help sites like QualityCounts.com stay open. Affiliate links cost you nothing but help me support my family. We do not allow paid reviews on this site. As an Amazon Associate I earn from qualifying purchases.  Also, you can donate to ben@qualitycounts.com via Zelle or PayPal.  Click here for the PayPal QR.  Click here for Bitcoin QR code or Bitcoin address: 39muDw6WpQV8j6EdA8eUBvT5iFDiVpVpiE
Home iHerb ReliableRx Amazon.com Contact
 Sign-up for newsletter 
 Newsletter Archive
 Newsletter via RSS Feed
 Research on Supplements
 Health Conditions
 Anti-aging Recommendations
 Insulin and Aging
 QualityCounts.com in Time
 Longevity Affiliates:

Recent Longevity News for the week ending 12/8/21

Only alcohol -- not caffeine, diet or lack of sleep -- might trigger heart rhythm condition - Science Daily, 11/24/21 - "

Latte lovers rejoice! Study reveals drinking coffee could lower the risk of Alzheimer’s disease - Science Daily, 11/23/21 - "Drinking more coffee gave positive results in relation to certain domains of cognitive function, specifically executive function which includes planning, self-control, and attention ... Higher coffee intake also seemed to be linked to slowing the accumulation of the amyloid protein in the brain, a key factor in the development of Alzheimer's disease ... If the average cup of coffee made at home is 240g, increasing to two cups a day could potentially lower cognitive decline by eight per cent after 18 months ... It could also see a five per cent decrease in amyloid accumulation in the brain over the same time period ... In Alzheimer's disease, the amyloid clumps together forming plaques which are toxic to the brain ... The study was unable to differentiate between caffeinated and de-caffeinated coffee, nor the benefits or consequences of how it was prepared (brewing method, the presence of milk and/or sugar etc)." -

Daily Aspirin Linked to Increased Risk of Heart Failure - Medscape, 11/24/21 - "In data from 30,827 patients at risk for HF enrolled in six observational studies, the hazard ratio (HR) for developing HF among those taking daily aspirin at baseline relative to those who were not was 1.26 (P ≤ .001) over 5.3 years of follow-up. In the 22,690 patients without a prior history of cardiovascular disease (CVD), the HF risk increase for exposure to daily aspirin was about the same (HR, 1.27 ... Interestingly, this study reported that aspirin use was associated with an increased risk of readmissions for HF ... Overall, the incidence rate of HF per 1000 person-years for the entire population before adjustment was 14.5 in the group on daily aspirin versus 5.9 in the nonaspirin group"

Gum Disease Bacteria a New Treatment Target for Alzheimer's? - Medscape, 11/23/21 - "Results from the phase 2/3 GAIN trial of atuzaginstat (Cortexyme Inc), which targets the gum bacteria Porphyromonas gingivalis (Pg), suggest the pathogen is a "potential driver of AD.""

Sacubitril/Valsartan May Alter Trajectory of Preclinical HFpEF - Medscape, 11/23/21 - "Sacubitril/valsartan (Entresto) appears to improve measures of cardiac structure and function compared with valsartan alone in asymptomatic preclinical heart failure with preserved ejection fraction ... Sacubitril/valsartan (Entresto) appears to improve measures of cardiac structure and function compared with valsartan alone in asymptomatic preclinical heart failure with preserved ejection fraction ... Preclinical heart failure with preserved ejection fraction (HFpEF), the dominant form of preclinical HF, is largely driven by CV compliance abnormalities. Sacubitril/valsartan, through preservation of natriuretic peptide (NP), may improve CV compliance, especially if introduced early in the disease process ... At baseline, the left atrial volume index (LAVI) was 33.2 mL/m2 using Doppler echocardiography and 50 mL/m2 using cardiac MRI. "The discrepancy you see with cardiac MRI is a notable feature in the literature, but maybe something that's not as widely appreciated as it should be," ... The primary outcome of change in maximal LAVI over 18 months by cardiac MRI was 6.9 mL/m2 with sacubitril/valsartan vs 0.7 mL/m2 with valsartan alone ... Sacubitril/valsartan was also associated with a significant change in left ventricular end-diastolic volume index (7.1 mL/m2 vs 1.4% mL/m2 ... Over a median 16.9 months of follow-up, sacubitril/valsartan reduced 24-hour pulse pressures by -4.2 mm Hg vs -1.2 mm Hg with valsartan alone ... Following the presentation, an audience member asked whether the results may endorse the use of sacubitril/valsartan as an antihypertensive — an indication already approved in some countries ... "That's a fascinating question," McDonald replied. "When you look at the mechanisms of action of this agent compared to other antihypertensive agents and, particularly its beneficial effect of vasoprotective peptides, there's good reason to suspect it may be of more benefit than standard therapies, especially in those people who've shown at risk for the development of cardiovascular events.""

Abstracts from this week:

Anti-osteoporotic potential of Lactobacillus plantarum AR237 and AR495 in ovariectomized mice J Func Foods, 12/21 - "Osteoporosis is a common skeletal disease in which bone resorption exceeds bone formation. Intestinal health has been linked to reduced osteoporosis. The aim of this study was to compare the anti-osteoporotic and intestinal health effects of two strains of Lactobacillus plantarum (AR237 and AR495) in ovariectomized (ovx) C57BL/6 mice. The results showed that AR495 significantly inhibited ovx-induced bone loss, reduced intestinal permeability, increased the expression of tight junction proteins, claudin-family proteins, zonula occludens-1 (ZO-1), and junctional adhesion molecule 3 (JAM-3) in ovx mice. Furthermore, AR495 inhibited bone resorption by modulating the receptor activator for nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) system, and ameliorated ovx-induced intestinal inflammatory responses. AR495 improved intestinal microbial stability, and increased the abundance of short-chain fatty acids (SCFA)-producing bacteria and fecal SCFA content of ovx mice. Overall, the findings of this study showed that AR495 was more effective than AR237 at treating osteoporosis" - [Nutra USA] -

Neat Tech Stuff / "How To's":


Health Focus (Head & Neck Cancer):